Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11015952 | PMC |
| http://dx.doi.org/10.1093/eurheartj/ehae028 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of Low Doses of Semaglutide on Weight Loss and Body Composition Among Women in Their Menopause.
Metab Syndr Relat Disord
January 2025
Clínica Rotger (Grupo Quirón), Vía Roma, Baleares, Spain.
Menopause is a complex period in women's life, when weight gain and predisposition to obesity are frequent. Moreover, even during menopause transition, women begin to lose lean mass up to 0.5% and, therefore, an increase in the percentage of fat mass with central distribution and an increased risk of metabolic syndrome.
View Article and Find Full Text PDFUse of Cardioprotective Adjuncts in Type 1 Diabetes.
Diabetes Ther
January 2025
Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010, Australia.
Type 1 diabetes is associated with excess cardiovascular risk, even after accounting for traditional cardiovascular risk factors, including glycaemia. Hence, there is an urgent need to document the metabolic abnormalities that contribute to the cardiovascular mortality gap in type 1 diabetes, and to examine whether cardioprotective type 2 diabetes medications prevent premature morbidity and mortality in this population.
View Article and Find Full Text PDFProteomic changes upon treatment with semaglutide in individuals with obesity.
Nat Med
January 2025
Data Science, Novo Nordisk A/S, Søborg, Denmark.
Obesity and type 2 diabetes are prevalent chronic diseases effectively managed by semaglutide. Here we studied the effects of semaglutide on the circulating proteome using baseline and end-of-treatment serum samples from two phase 3 trials in participants with overweight or obesity, with or without diabetes: STEP 1 (n = 1,311) and STEP 2 (n = 645). We identified evidence supporting broad effects of semaglutide, implicating processes related to body weight regulation, glycemic control, lipid metabolism and inflammatory pathways.
View Article and Find Full Text PDFEffectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes.
Diabetes Technol Ther
January 2025
Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, Colorado, USA.
Adults with type 1 diabetes (T1D) are increasingly overweight or obese, in part due to intensive insulin therapy. Newer non-insulin medications targeting both hyperglycemia and weight loss are approved for people with type 2 diabetes. These drugs also reduce cardiovascular disease, the major cause of mortality in people with diabetes.
View Article and Find Full Text PDFAnti-consumption agents: Tirzepatide and semaglutide for treating obesity-related diseases and addictions, and improving life expectancy.
Prog Cardiovasc Dis
December 2024
Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, MO, United States of America.
American culture encourages overconsumption, fueled by ubiquitous availability and pervasive marketing of ultra-processed foods and other addictive substances. This chronic overindulgence has contributed to rising rates of obesity, type 2 diabetes (T2D), substance abuse, mental health disorders and premature mortality. Glucose-like peptide-1 agonists (GLP-1RAs) affect the brain's reward pathway that mediates addiction to foods and various other substances.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!